Panel Embraces Maximum Viral Suppression as Goal of Therapy; Drug Company Bonanza Creates Headaches for Third-Party Payers and AIDS Treatment Educators Eleventh hour backstage skullduggery stymied by unified community "And What Rough Beast, Its Hour Come Round at Last, Slouches…
Opportunistic Infections in the Era of HAART - A Report from the 4th Conference on Retroviruses HIV RNA as guide to risk Protease inhibitors (ritonavir, indinavir and nelfinavir) in combination with reverse transcriptase inhibitors (commonly referred to as "HAART," for…
HIV-Infected Kids Choke in the Dust of Adult Advances While Their Advocates Struggle to Maintain Funding Two to three year lag As the AIDS epidemic nears the end of its second decade, pediatric AIDS research has become a flash-point for…
When it comes to corporate positioning for protease inhibitor market share, every company has a yarn to spin. Merck loyalists insist that theirs be used first-line because it's so powerful and, "after all, really requires multiple mutations in order to…
Government Study Finds Protease Based Triple Combination Keeps Patients Alive Longer Than Double Nuke Changing the standard of care Results of AIDS Clinical Trials Group (ACTG) 320, one of the most important studies of triple-drug antiviral therapy in people with…
Eluding Public Scrutiny, Nelfinavir Becomes the Fourth Protease Inhibitor to Hit the Pharmacy Shelves Resistance enigma The US Food & Drug Administration (FDA), which will soon be under the control of Acting Commissioner Dr. Michael Friedman when Commissioner Dr. David…
"Very effective" therapies for: Pneumocystis pneumonia (PCP) tuberculosis (TB) cryptococcosis histoplasmosis "Effective, but toxic" therapies for: toxoplasmic encephalitis "Moderately effective" therapies for: Mycobacterium avium complex (MAC) cytomegalovirus (CMV) "No active treatments" for: cryptosporidiosis/microsporidiosis progressive multifocal leukoencephalopathy (PML)
Opportunistic Infections Continue to Vex the Lives of PWAs as Long As Immunodeficiency Remains 'Postponing the inevitable' Michael Marco and his TAG colleagues working within TAG's Opportunistic Infections Committee (Theo Smart, Laura Morrison, Tim Horn, Paul Dietz, Mark Harrington) released…
Nearly Everyone Agrees On the Need for 'Strategy' Type Clinical Studies -- And That's Where Consensus Ends An intrepid Dr. Lange scales Mt. Sinai First there was the CPCRA's "Moving Target" protocol, which entailed half a decade of arduous, dog-chasing-its-tail…
Activist Epistler Chronicles Frightening Tales of Multiply Resistant HIV from D.C. Principles Panel Toxic cocktail The NIH panel convened late last November to develop new state-of-the-art guidelines for the treatment of HIV infection included a series of provocative (some would…